WASHINGTON–(BUSINESS WIRE)–#COVID19–Xlear has filed a Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA) seeking approval to make claims that the nasal spray is approved for use in preventing SARS-CoV-2 (COVID-19) transmission and infection. The Pre-EUA is a first step in seeking formal authorization of Xlear Nasal Spray as tool to help in combatting COVID-19.
Xlear previously filed a pre-EUA seeking approval for use of the nasal spray as a medical device in combatting COVID-19. However, because the FDA determined that Xlear �works against the virus, the FDA told Xlear it would need to be considered as a drug or combination product EUA.
Seeing that the FDA says Xlear works against the virus, we have decided to seek EUA approval as a drug, said Nathan Jones, Xlears CEO.
Xlears Pre-EUA Request is based on recent studies showing the nasal spray is:
Xlear is currently sold in over 50,000 pharmacies, grocery stores, and online as a nasal spray. Xlear doesnt require the EUA to be sold and usedwe only need an EUA to be able to inform people about the benefits of using Xlear to protect themselves from COVID-19. Its insane. Without the EUA, the Federal Trade Commission wont let us simply inform people about new, published, independent scientific studies, Jones added.
We hope to move forward quickly with FDA to address gaps in current prevention and treatment strategies against SARS-CoV-2. People should be using Xlear as part of a layered defense to prevent getting COVID-19. If everyone used Xlear, in addition to taking other steps recommended by public health officials, we believe we could help the nation defeat COVID-19 faster, Jones added.
More information on Xlear: https://xlear.com/
Contacts
Jeff Gulko
617.304.7339
jeff@thegulkogroup.com
Partnership expands spectrum of Secarna's capabilities for the development of targeted ASOs beyond antibodies and…
FourKites is the first real-time visibility platform participating in the SSC CHICAGO--(BUSINESS WIRE)--Leading real-time supply…
ALMERE, Netherlands--(BUSINESS WIRE)--Hopewind (SHANGHAI STOCK EXCHANGE Code: 603063) has been officially nominated for the 2024…
TOKYO & NEW YORK & DÜSSELDORF, Germany--(BUSINESS WIRE)--Asahi Kasei Corp. (TOKYO:3407) today announces that it…
KUALA LUMPUR, MALAYSIA - Media OutReach Newswire - 28 May 2024 - Kenanga Investment Bank…
BANGKOK, THAILAND - Media OutReach Newswire - 28 May 2024 - On May 19-20, 2024,…